Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S (the "Company") was submitted on January 10, 2025. The report discloses a material modification to the rights of security holders regarding the Company's American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate actions regarding share structure rather than financial performance.
Material Changes
- ADS Ratio Change: The Board of Directors approved changing the ADS Ratio from 1 ADS representing 10 ordinary shares to 1 ADS representing 50 ordinary shares.
- Effective Date: The change is expected to become effective on or about January 14, 2025. This date was extended by one day from the original January 13, 2025 target due to a Nasdaq Capital Markets closure observing the passing of President Jimmy Carter.
- Reverse Split Mechanics: The change functions as a one-for-five reverse ADS split. Holders will receive one new ADS for every five existing ADSs held.
- Trading Symbol: ADSs will continue to trade on The Nasdaq Capital Market under the ticker symbol "EVAX."
Outlook, Risks, and Management Commentary
- Liquidity Intent: The Company states the change is intended to further support liquidity in its ADSs.
- Price Expectation: The ADS trading price is expected to increase proportionally to the ratio change.
- Risk Disclosure: The Company provides no assurance that the post-change trading price will be proportionally equal to or greater than the pre-change price, nor that the change will positively affect liquidity.
- Fractional Shares: No fractional new ADSs will be issued. Fractional entitlements will be aggregated, sold by the Depositary, and net cash proceeds distributed to holders after fees and expenses.
Investor Verification Checklist
- Confirm the exact effective date of the ADS Ratio Change (expected January 14, 2025).
- Verify the mechanics of the one-for-five exchange for certificated versus uncertificated ADS holders.
- Review the press release (Exhibit 99.1) for specific details on the distribution of proceeds from fractional share sales.
- Monitor the trading price of "EVAX" on Nasdaq Capital Markets following the effective date to assess actual liquidity impact.